Chimeric Antigen Receptor T-cell and Cellular Therapies for the Treatment of cAncer or BLood Diseases: Evaluation of Reporting of Adverse Events
CAR-T cells and cellular therapies may lead to various adverse reactions. This study investigates reports of different toxicities for cellular therapies in the World Health Organization's (WHO) global database of individual safety case reports (VigiBase).
Adverse Drug Reactions|Cancer
DRUG: CAR T-cell and Cellular Therapies
Number of patients with adverse events with significant over-reporting CAR-T cells and other cellular therapies, Identification and report of various toxicities of cellular therapies., Case reported in the World Health Organization (WHO) of individual safety case reports to January 2020
Causality assessment of reported adverse events according to the WHO system, Case reported in the World Health Organization (WHO) of individual safety case reports to January 2020|Description of the type of adverse event depending on the class and the target of cellular therapy, Case reported in the World Health Organization (WHO) of individual safety case reports to January 2020|Description of the duration of treatment when the toxicity happens and the time to onset, Case reported in the World Health Organization (WHO) of individual safety case reports to January 2020|Description of the drug-drug interactions associated with adverse events, Case reported in the World Health Organization (WHO) of individual safety case reports to January 2020|Description of the pathologies (cancer) for which the incriminated drugs have been prescribed, Case reported in the World Health Organization (WHO) of individual safety case reports to January 2020|Description of the population of patients having an adverse event, Case reported in the World Health Organization (WHO) of individual safety case reports to January 2020
CAR-T cells and cellular therapies are responsible of a wide range of side effects.The investigators use VigiBase, the World Health Organization (WHO) database of individual safety case reports, to identify cases of adverse drug reactions following treatment with cellular therapies